DEVELOPMENT PIPELINE
We are leveraging our proprietary SNIPRx platform to discover, validate and build a robust clinical and pre-clinical pipeline of SL-based oncology therapeutics.
Development Pipeline
Program
Tumor Lesion
- Discovery Discovery
- IND-Enabling IND-Enabling
- Ph 1/2 Phase 1/2
- Pivotal Pivotal
Rights
Lunresertib
PKMYT1 Inhibitor
CCNE1,
FBXW7 + others
FBXW7 + others
- Ph 1/2
Ph2 CCTG ISTs
- Ph 1/2
Ph1 MYTHIC: Mono + Camonsertib Combo
- Ph 1/2
Ph1 MAGNETIC: Gemcitabine Combo
- Ph 1/2
Ph1 MINOTAUR: FOLFIRI Combo
- Ph 1/2
Ph 1 Carboplatin/paclitaxel Combo IST
- Ph 1/2
Ph1/1b Debio 0123 Combination
Camonsertib
ATR Inhibitor
ATM + 16 lesions
- Ph 1/2
Ph2 TAPISTRY
- Ph 1/2
Ph1b/2 Morpheus-Lung
- Ph 1/2
Ph1/2 TRESR: Mono + PARP (talazoparib) Combo
- Ph 1/2
Ph1/2 ATTACC: PARP (olaparib/niraparib) Combo
- Ph 1/2
Ph1/2 TRESR: Gemcitabine Combo
Clinical Trial
Ph2 CCTG ISTs
Progress
Phase 1/2
Clinical Trial
Ph1 MYTHIC: Mono + Camonsertib Combo
Progress
Phase 1/2
Clinical Trial
Ph1 MAGNETIC: Gemcitabine Combo
Progress
Phase 1/2
Clinical Trial
Ph1 MINOTAUR: FOLFIRI Combo
Progress
Phase 1/2
Clinical Trial
Ph 1 Carboplatin/paclitaxel Combo IST
Progress
Phase 1/2
Clinical Trial
Ph1/1b Debio 0123 Combination
Progress
Phase 1/2
Rights
Repare
Clinical Trial
Ph2 TAPISTRY
Progress
Phase 1/2
Clinical Trial
Ph1b/2 Morpheus-Lung
Progress
Phase 1/2
Clinical Trial
Ph1/2 TRESR: Mono + PARP (talazoparib) Combo
Progress
Phase 1/2
Clinical Trial
Ph1/2 ATTACC: PARP (olaparib/niraparib) Combo
Progress
Phase 1/2
Clinical Trial
Ph1/2 TRESR: Gemcitabine Combo
Progress
Phase 1/2
Rights
Repare
Clinical Trial
Ph1 LIONS Monotherapy
Progress
Phase 1/2
Rights
Repare
Progress
IND. Enabling
Rights
Repare
Progress
Discovery
Rights
Repare
Progress
Discovery
Rights
Bristol Myers Squibb